Literature DB >> 24987110

Microsatellite instability detection by next generation sequencing.

Stephen J Salipante1, Sheena M Scroggins1, Heather L Hampel2, Emily H Turner1, Colin C Pritchard3.   

Abstract

BACKGROUND: Microsatellite instability (MSI) is a useful phenotype in cancer diagnosis and prognosis. Nevertheless, methods to detect MSI status from next generation DNA sequencing (NGS) data are underdeveloped.
METHODS: We developed an approach to detect the MSI phenotype using NGS (mSINGS). The method was used to evaluate mononucleotide microsatellite loci that were incidentally sequenced after targeted gene enrichment and could be applied to gene or exome capture panels designed for other purposes. For each microsatellite locus, the number of differently sized repeats in experimental samples were quantified and compared to a population of normal controls. Loci were considered unstable if the experimental number of repeats was statistically greater than in the control population. MSI status was determined by the fraction of unstable microsatellite loci.
RESULTS: We examined data from 324 samples generated using targeted gene capture assays of 3 different sizes, ranging from a 0.85-Mb to a 44-Mb exome design and incorporating from 15 to 2957 microsatellite markers. When we compared mSING results to MSI-PCR as a gold standard for 108 cases, we found the approach to be both diagnostically sensitive (range of 96.4% to 100% across 3 panels) and specific (range of 97.2% to 100%) for determining MSI status. The fraction of unstable microsatellite markers calculated from sequencing data correlated with the number of unstable loci detected by conventional MSI-PCR testing.
CONCLUSIONS: NGS data can enable highly accurate detection of MSI, even from limited capture designs. This novel approach offers several advantages over existing PCR-based methods.
© 2014 American Association for Clinical Chemistry.

Entities:  

Mesh:

Year:  2014        PMID: 24987110     DOI: 10.1373/clinchem.2014.223677

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  121 in total

1.  SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Authors:  Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

2.  3'-UTR poly(T/U) repeat of EWSR1 is altered in microsatellite unstable colorectal cancer with nearly perfect sensitivity.

Authors:  Johanna Kondelin; Sari Tuupanen; Alexandra E Gylfe; Mervi Aavikko; Laura Renkonen-Sinisalo; Heikki Järvinen; Jan Böhm; Jukka-Pekka Mecklin; Claus L Andersen; Pia Vahteristo; Esa Pitkänen; Lauri A Aaltonen
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

3.  Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers.

Authors:  Luke K Genutis; Jerneja Tomsic; Ralf A Bundschuh; Pamela L Brock; Michelle D Williams; Sameek Roychowdhury; Julie W Reeser; Wendy L Frankel; Mohammed Alsomali; Mark J Routbort; Russell R Broaddus; Paul E Wakely; John E Phay; Christopher J Walker; Albert de la Chapelle
Journal:  Thyroid       Date:  2019-03-27       Impact factor: 6.568

4.  Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations.

Authors:  Jaclyn F Hechtman; Sumit Middha; Zsofia K Stadler; Ahmet Zehir; Michael F Berger; Efsevia Vakiani; Martin R Weiser; Marc Ladanyi; Leonard B Saltz; David S Klimstra; Jinru Shia
Journal:  Fam Cancer       Date:  2017-10       Impact factor: 2.375

Review 5.  Whole-Genome Sequencing in Cancer.

Authors:  Eric Y Zhao; Martin Jones; Steven J M Jones
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

Review 6.  Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.

Authors:  Valerie Lee; Adrian Murphy; Dung T Le; Luis A Diaz
Journal:  Oncologist       Date:  2016-07-13

7.  Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.

Authors:  Emmanuel S Antonarakis; Josep M Piulats; Marine Gross-Goupil; Jeffrey Goh; Kristiina Ojamaa; Christopher J Hoimes; Ulka Vaishampayan; Ranaan Berger; Ahmet Sezer; Tuomo Alanko; Ronald de Wit; Chunde Li; Aurelius Omlin; Giuseppe Procopio; Satoshi Fukasawa; Ken-Ichi Tabata; Se Hoon Park; Susan Feyerabend; Charles G Drake; Haiyan Wu; Ping Qiu; Jeri Kim; Christian Poehlein; Johann Sebastian de Bono
Journal:  J Clin Oncol       Date:  2019-11-27       Impact factor: 44.544

8.  Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.

Authors:  Zishuo I Hu; Jinru Shia; Zsofia K Stadler; Anna M Varghese; Marinela Capanu; Erin Salo-Mullen; Maeve A Lowery; Luis A Diaz; Diana Mandelker; Kenneth H Yu; Alice Zervoudakis; David P Kelsen; Christine A Iacobuzio-Donahue; David S Klimstra; Leonard B Saltz; Ibrahim H Sahin; Eileen M O'Reilly
Journal:  Clin Cancer Res       Date:  2018-01-24       Impact factor: 12.531

9.  Classification and characterization of microsatellite instability across 18 cancer types.

Authors:  Ronald J Hause; Colin C Pritchard; Jay Shendure; Stephen J Salipante
Journal:  Nat Med       Date:  2016-10-03       Impact factor: 53.440

10.  MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair.

Authors:  Christopher J Walker; Mario A Miranda; Matthew J O'Hern; James S Blachly; Cassandra L Moyer; Jennifer Ivanovich; Karl W Kroll; Ann-Kathrin Eisfeld; Caroline E Sapp; David G Mutch; David E Cohn; Ralf Bundschuh; Paul J Goodfellow
Journal:  Hum Mutat       Date:  2016-08-08       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.